Clinical Trial Update: Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer [Phase 2]

View source ↗

Summary

Phase II study evaluating sipuleucel-T with indoximod for refractory metastatic prostate cancer has completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Indoximod (indoximod)
• sipuleucel-T (sipuleucel-T)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Metastatic Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-04-03